Naprosyn Ec (Naproxen)

Naprosyn Ec is an NSAID that acts on inflammatory and pain pathways in several musculoskeletal and gynecologic conditions.

• Mild to moderate pain: provides analgesic relief for headaches, dental pain, and minor injuries.
• Rheumatoid arthritis: helps control joint inflammation and stiffness.
• Osteoarthritis: reduces chronic joint pain and improves mobility.
• Musculoskeletal pain: alleviates strain, sprain and back pain.
• Dysmenorrhea: eases menstrual cramps and associated discomfort.

• Naproxen exerts its effect by non‑selectively inhibiting cyclooxygenase‑1 (COX‑1) and cyclooxygenase‑2 (COX‑2) enzymes, which blocks the conversion of arachidonic acid to prostaglandins. The resulting decrease in prostaglandin synthesis diminishes inflammation, pain signaling, and fever generation throughout the body.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Gastrointestinal upset: dyspepsia, nausea, or abdominal pain.
• Headache: mild to moderate intensity.
• Dizziness or vertigo.
• Rash or mild skin irritation.
• Elevated blood pressure.
• Mild renal function changes.

Serious or Rare Side Effects

• Gastrointestinal ulceration or bleeding.
• Cardiovascular events such as myocardial infarction or stroke.
• Severe renal impairment or failure.
• Hepatic injury or elevated liver enzymes.
• Life‑threatening skin reactions (e.g., Stevens‑Johnson syndrome).
• Anaphylaxis or severe hypersensitivity reactions.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

• Assess gastrointestinal risk: review history of ulcers, bleeding, or chronic NSAID use.
• Evaluate cardiovascular profile: consider existing heart disease or risk factors.
• Monitor renal function: especially in patients with dehydration or pre‑existing kidney disease.
• Use the lowest effective dose for the shortest duration needed.
• Avoid use in patients with known hypersensitivity to naproxen or other NSAIDs.
• Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Naproxen can alter the pharmacodynamics or pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased risk of serious bleeding.
• Other NSAIDs or aspirin: additive gastrointestinal toxicity.
• Selective serotonin reuptake inhibitors (SSRIs): heightened bleeding tendency.
• ACE inhibitors or ARBs: possible reduction in antihypertensive effect and renal function.
• Lithium: naproxen may raise lithium serum concentrations.

Moderate Interactions (Monitor Closely)

• Diuretics: may reduce renal perfusion when combined.
• Corticosteroids: increased risk of gastrointestinal ulceration.
• Methotrexate: potential for elevated methotrexate levels.
• Antihypertensives (e.g., beta‑blockers): possible attenuation of blood pressure control.
• Oral hypoglycemics: naproxen may affect glucose control.